Spots Global Cancer Trial Database for stage iii renal cell cancer ajcc v8

Every month we try and update this database with for stage iii renal cell cancer ajcc v8 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer	NCT05122546	Advanced Clear ... Advanced Papill... Advanced Renal ... Advanced Sarcom... Metastatic Clea... Metastatic Papi... Metastatic Rena... Metastatic Sarc... Stage III Renal... Stage IV Renal ... Unresectable Cl... Unresectable Re...	Cabozantinib S-... Clostridium but... Nivolumab	18 Years -	City of Hope Medical Center
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2	NCT03284385	Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Stage III Renal... Stage IV Renal ...	Adavosertib	18 Years -	National Cancer Institute (NCI)
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	NCT02496208	Bladder Small C... Bladder Squamou... Bladder Urothel... Clear Cell Rena... Invasive Bladde... Invasive Bladde... Invasive Sarcom... Kidney Medullar... Malignant Genit... Malignant Solid... Penile Carcinom... Penile Squamous... Renal Cell Carc... Renal Pelvis Ur... Sarcomatoid Ren... Stage III Bladd... Stage III Penil... Stage III Renal... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe...	Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study	NCT03793166	Clear Cell Rena... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Mali... Sarcomatoid Ren... Stage III Renal... Stage IV Renal ...	Biospecimen Col... Cabozantinib Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab Quality-of-Life... Questionnaire A...	18 Years -	National Cancer Institute (NCI)
Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery	NCT04370509	Metastatic Clea... Recurrent Clear... Stage III Renal... Stage IV Renal ... Clear Cell Rena...	Axitinib (VEGF-... Cytoreductive N... Metastasectomy ... Pembrolizumab	18 Years -	University of California, San Francisco
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies	NCT02419495	Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re...	Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan	18 Years -	M.D. Anderson Cancer Center
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer	NCT03587662	Metastatic Kidn... Metastatic Rena... SMARCB1 Negativ... Stage III Renal... Stage IV Renal ...	Doxorubicin Doxorubicin Hyd... Gemcitabine Gemcitabine Hyd... Ixazomib Ixazomib Citrat...	12 Years -	M.D. Anderson Cancer Center
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	NCT02496208	Bladder Small C... Bladder Squamou... Bladder Urothel... Clear Cell Rena... Invasive Bladde... Invasive Bladde... Invasive Sarcom... Kidney Medullar... Malignant Genit... Malignant Solid... Penile Carcinom... Penile Squamous... Renal Cell Carc... Renal Pelvis Ur... Sarcomatoid Ren... Stage III Bladd... Stage III Penil... Stage III Renal... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe...	Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	NCT04514484	Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi...	Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax	NCT05092373	Advanced Breast... Advanced Endome... Advanced Fallop... Advanced Hepato... Advanced Malign... Advanced Malign... Advanced Malign... Advanced Ovaria... Advanced Primar... Advanced Renal ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Malignant Abdom... Malignant Solid... Metastatic Brea... Metastatic Endo... Metastatic Fall... Metastatic Hepa... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Metastatic Rena... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Fallo... Stage III Hepat... Stage III Ovari... Stage III Prima... Stage III Renal... Stage III Uteri... Stage IIIA Fall... Stage IIIA Hepa... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA Uter... Stage IIIA1 Fal... Stage IIIA1 Ova... Stage IIIA2 Fal... Stage IIIA2 Ova... Stage IIIB Fall... Stage IIIB Hepa... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIB Uter... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Fallop... Stage IV Hepato... Stage IV Ovaria... Stage IV Primar... Stage IV Renal ... Stage IV Uterin... Stage IVA Fallo... Stage IVA Hepat... Stage IVA Ovari... Stage IVA Prima... Stage IVA Uteri... Stage IVB Fallo... Stage IVB Hepat... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri...	Atezolizumab Cabozantinib S-... Nab-paclitaxel Tumor Treating ...	18 Years -	M.D. Anderson Cancer Center
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer	NCT04022343	Clear Cell Rena... Renal Cell Carc... Stage III Renal...	Cabozantinib	18 Years -	Emory University
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer	NCT05122546	Advanced Clear ... Advanced Papill... Advanced Renal ... Advanced Sarcom... Metastatic Clea... Metastatic Papi... Metastatic Rena... Metastatic Sarc... Stage III Renal... Stage IV Renal ... Unresectable Cl... Unresectable Re...	Cabozantinib S-... Clostridium but... Nivolumab	18 Years -	City of Hope Medical Center
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	NCT06265285	Advanced Esopha... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Carc... Gastroesophagea... Hepatocellular ... Locally Advance... Lung Non-Small ... Malignant Solid... Metastatic Colo... Metastatic Cuta... Metastatic Esop... Metastatic Head... Metastatic Urot... Recurrent Esoph... Recurrent Head ... Renal Cell Carc... Stage III Renal... Stage IV Colore... Stage IV Cutane... Stage IV Renal ... Unresectable Cu... Unresectable Es... Urothelial Carc...	Home Health Enc... Nivolumab Patient Monitor... Questionnaire A...	18 Years -	Mayo Clinic
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer	NCT05122546	Advanced Clear ... Advanced Papill... Advanced Renal ... Advanced Sarcom... Metastatic Clea... Metastatic Papi... Metastatic Rena... Metastatic Sarc... Stage III Renal... Stage IV Renal ... Unresectable Cl... Unresectable Re...	Cabozantinib S-... Clostridium but... Nivolumab	18 Years -	City of Hope Medical Center
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2	NCT03284385	Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Stage III Renal... Stage IV Renal ...	Adavosertib	18 Years -	National Cancer Institute (NCI)
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies	NCT04902040	Advanced Bladde... Advanced Lung N... Advanced Malign... Advanced Melano... Advanced Merkel... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage III Bladd... Stage III Lung ... Stage III Renal... Stage IIIA Blad... Stage IIIA Lung... Stage IIIB Blad... Stage IIIB Lung... Stage IIIC Lung... Stage IV Bladde... Stage IV Lung C... Stage IV Renal ... Stage IVA Bladd... Stage IVA Lung ... Stage IVB Bladd... Stage IVB Lung ...	Atezolizumab Avelumab Durvalumab Nivolumab Pembrolizumab Plinabulin Radiation Thera...	18 Years -	M.D. Anderson Cancer Center
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer	NCT03829111	Advanced Renal ... Clear Cell Rena... Metastatic Rena... Stage III Renal... Stage IV Renal ... Unresectable Re...	Clostridium but... Ipilimumab Nivolumab	18 Years -	City of Hope Medical Center
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma	NCT06049576	Clear Cell Rena... Sarcomatoid Ren... Stage III Renal... Stage IV Renal ...	Biospecimen Col... Bone Scan Computed Tomogr... Ipilimumab Magnetic Resona... Myrciaria dubia... Nivolumab	18 Years -	City of Hope Medical Center
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma	NCT03274258	Kidney Medullar... Loss of INI 1 P... Stage III Renal... Stage IV Renal ...	Ipilimumab Nivolumab	18 Years -	M.D. Anderson Cancer Center
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies	NCT04902040	Advanced Bladde... Advanced Lung N... Advanced Malign... Advanced Melano... Advanced Merkel... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage III Bladd... Stage III Lung ... Stage III Renal... Stage IIIA Blad... Stage IIIA Lung... Stage IIIB Blad... Stage IIIB Lung... Stage IIIC Lung... Stage IV Bladde... Stage IV Lung C... Stage IV Renal ... Stage IVA Bladd... Stage IVA Lung ... Stage IVB Bladd... Stage IVB Lung ...	Atezolizumab Avelumab Durvalumab Nivolumab Pembrolizumab Plinabulin Radiation Thera...	18 Years -	M.D. Anderson Cancer Center
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study	NCT05361720	Advanced Clear ... Metastatic Clea... Stage III Renal... Stage IV Renal ...	Cabozantinib Ipilimumab Nivolumab	18 Years -	Vanderbilt-Ingram Cancer Center
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes	NCT04501913	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Hepatobiliary N... Malignant Diges... Malignant Femal... Malignant Genit... Malignant Neopl... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Stage 0 Colorec... Stage 0a Bladde... Stage 0is Bladd... Stage I Bladder... Stage I Cervica... Stage I Colorec... Stage I Ovarian... Stage I Prostat... Stage I Renal C... Stage I Uterine... Stage IA Cervic... Stage IA Ovaria... Stage IA Uterin... Stage IA1 Cervi... Stage IA2 Cervi... Stage IB Cervic... Stage IB Ovaria... Stage IB Uterin... Stage IB1 Cervi... Stage IB2 Cervi... Stage IC Ovaria... Stage II Bladde... Stage II Cervic... Stage II Colore... Stage II Ovaria... Stage II Prosta... Stage II Renal ... Stage II Uterin... Stage IIA Cervi... Stage IIA Color... Stage IIA Ovari... Stage IIA Prost... Stage IIA1 Cerv... Stage IIA2 Cerv... Stage IIB Cervi... Stage IIB Color... Stage IIB Ovari... Stage IIB Prost... Stage IIC Color... Stage IIC Prost... Stage III Bladd... Stage III Cervi... Stage III Color... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Uteri... Stage IIIA Blad... Stage IIIA Cerv... Stage IIIA Colo... Stage IIIA Ovar... Stage IIIA Pros... Stage IIIA Uter... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Blad... Stage IIIB Cerv... Stage IIIB Colo... Stage IIIB Ovar... Stage IIIB Pros... Stage IIIB Uter... Stage IIIC Colo... Stage IIIC Ovar... Stage IIIC Pros... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Bladde... Stage IV Cervic... Stage IV Colore... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Uterin... Stage IVA Bladd... Stage IVA Cervi... Stage IVA Color... Stage IVA Ovari... Stage IVA Prost... Stage IVA Uteri... Stage IVB Bladd... Stage IVB Cervi... Stage IVB Color... Stage IVB Ovari... Stage IVB Prost... Stage IVB Uteri... Stage IVC Color...	Patient Monitor... Questionnaire A...	18 Years -	City of Hope Medical Center
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer	NCT04022343	Clear Cell Rena... Renal Cell Carc... Stage III Renal...	Cabozantinib	18 Years -	Emory University
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery	NCT03334409	Clear Cell Rena... Metastatic Clea... Stage III Renal... Stage IV Renal ... Unresectable Re...	Ascorbic Acid Pazopanib Hydro...	18 Years -	Academic and Community Cancer Research United
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer	NCT05012371	Advanced Clear ... Metastatic Clea... Stage III Renal... Stage IV Renal ...	Cabozantinib Everolimus Lenvatinib Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study	NCT05327686	Metastatic Rena... Stage III Renal... Stage IV Renal ... Unresectable Re...	Avelumab Axitinib Cabozantinib Ipilimumab Lenvatinib Nivolumab Pembrolizumab Stereotactic Ab...	18 Years -	NRG Oncology
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer	NCT03829111	Advanced Renal ... Clear Cell Rena... Metastatic Rena... Stage III Renal... Stage IV Renal ... Unresectable Re...	Clostridium but... Ipilimumab Nivolumab	18 Years -	City of Hope Medical Center
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study	NCT05327686	Metastatic Rena... Stage III Renal... Stage IV Renal ... Unresectable Re...	Avelumab Axitinib Cabozantinib Ipilimumab Lenvatinib Nivolumab Pembrolizumab Stereotactic Ab...	18 Years -	NRG Oncology
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	NCT06265285	Advanced Esopha... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Carc... Gastroesophagea... Hepatocellular ... Locally Advance... Lung Non-Small ... Malignant Solid... Metastatic Colo... Metastatic Cuta... Metastatic Esop... Metastatic Head... Metastatic Urot... Recurrent Esoph... Recurrent Head ... Renal Cell Carc... Stage III Renal... Stage IV Colore... Stage IV Cutane... Stage IV Renal ... Unresectable Cu... Unresectable Es... Urothelial Carc...	Home Health Enc... Nivolumab Patient Monitor... Questionnaire A...	18 Years -	Mayo Clinic
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer	NCT04981509	Hereditary Leio... Papillary Renal... Renal Cell Carc... Sporadic Papill... Stage III Renal... Stage IV Renal ...	Atezolizumab Bevacizumab Biopsy Biospecimen Col... Bone Scan Computed Tomogr... Computed Tomogr... Erlotinib Magnetic Resona... Positron Emissi... Sodium Fluoride...	12 Years -	National Cancer Institute (NCI)
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies	NCT02419495	Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re...	Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan	18 Years -	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: